The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy
Open accessAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control. Mechanistically, GLP-1 signaling modulates immune and inflammatory pathways, regulates autophagy and pyroptosis, alleviates endoplasmic reticulum stress, and interacts with the gut microbiome. These pleiotropic effects provide a rationale for exploring their role in multiple organ systems. Clinical trials have demonstrated cardiovascular and renal protection, leading to additional approvals in high-risk populations. Early data also suggest potential benefits in liver disease, obstructive sleep apnea, chronic respiratory disorders, neurodegenerative and psychiatric conditions, reproductive dysfunction, obesity-associated cancers, and sepsis, although these remain investigational. Therefore, this review aims to synthesize the evidence on the mechanistic expansion of GLP-1RAs from metabolic regulators to systemic modulators of inflammation, autophagy, and organ protection, and explores their therapeutic repurposing across diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our results show pleiotropic anti-inflammatory and antioxidant effects that may mechanistically underlie the cardiovascular, hepatic, and renal protection consistently seen in large-scale cardiovascular outcome studies (45, 46), in addition to their well-established benefits on glycemic control and weight reduction (47, 48).”
From Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis (2026) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“…signi fi cantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023; Marso et al., 2016a).”
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638 · cited 1×
“For example, following the induction of intestinal ischemia in humans, a rapid increase in GLP-1 secretion was observed, suggesting a link between endogenous LPS translocation and GLP-1 activation under conditions of barrier dysfunction (Cani et al., 2007; Lebrun et al., 2017).”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“…signi fi cantly reduces the risk of major adverse cardiovascular events (MACE), leading to FDA approval for lowering the risk of cardiovascular death, myocardial infarction, or stroke in overweight or obese adults with established cardiovascular disease (Lincoff et al., 2023; Marso et al., 2016a).”
Biological Functions of Autophagy Genes: A Disease Perspective
Levine, B., & Kroemer, G. (2019) · Cell · doi:10.1016/j.cell.2018.09.048 · Cited by 2,832
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“…short-duration agents like exenatide, to intermediate-duration formulations such as liraglutide, and further to advanced long-acting options including dulaglutide and semaglutide (The two products received approval for marketing in the U.S. in 2014 and 2017, respectively) (Pfeffer et al., 2015).”
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964 · cited 1×
“Exenatide, the fi rst GLP-1RA approved in 2005, demonstrated clinical ef fi cacy but its low homology with human GLP-1 and gastrointestinal side effects restricted widespread use (Muttenthaler et al., 2021).”
Cited by
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 11
“Treatment with semaglutide has been associated with preferential reductions in visceral adipose tissue mass, improvements in body fat distribution, and decreases in circulating lipid intermediates linked to insulin resistance [30,31].”
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734549 · Cited by 4
Iwasaki, Y., Shimada, T., Kishimori, T., Kato, T., Koike, J., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113072 · Cited by 2
Metadata
- Authors
- Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H.
- Affiliations
- Kunming University of Science and Technology (CN)
- Corresponding author
- Chen, Guobing
- Su, Heng
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2025-09-11
- Volume
- 16
- Pages
- 1675552-1675552
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC12461214
- OpenAlex
- W4414131365
- Cited by
- 36
- References
- 141
- Citations by year
- 2026: 33 · 2025: 3
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, pleiotropy, inflammation, autophagy, pyroptosis, endoplasmic reticulum stress, gut microbiota, cardioprotection, renal protection, liver disease, obstructive sleep apnea, neurodegenerative diseases, mental illness, reproductive disorders, obesity-related cancer, sepsis, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy. https://app.cochat.ai/papers/10.3389/fphar.2025.1675552
- The paper
- Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025). GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1675552
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.